Innovent Biologics, Inc. (HKG:1801)
54.90
+1.15 (2.14%)
May 2, 2025, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
1.77M HKD
Profits / Employee
-17.80K HKD
Market Cap
90.48B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BeiGene | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
WuXi Biologics | 12,575 |
Alibaba Health Information Technology | 1,435 |
Akeso | 2,778 |
Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
CSPC Pharmaceutical Group | 21,400 |
Innovent Biologics News
- 5 days ago - Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies - PRNewsWire
- 7 days ago - Innovent Biologics Inc (IVBIY) Showcases Groundbreaking Preclinical Data at AACR 2025 | IVBIY ... - GuruFocus
- 7 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific ... - GuruFocus
- 7 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs - PRNewsWire
- 9 days ago - Innovent Biologics Inc (IVBIY) Secures NMPA Approval for Limertinib as First-Line Treatment for ... - GuruFocus
- 9 days ago - Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ... - GuruFocus
- 9 days ago - Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer - PRNewsWire
- 11 days ago - Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363(PD-1/IL-2α-bias)and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting - PRNewsWire